SecurityCYTX / Cytori Therapeutics, Inc. (23283K105)
President and CEOHEDRICK MARC H
IndustrySurgical and Medical Instruments and Apparatus
Institutional Owners37
Institutional Shares4,762,305 - 7.73%
Common Shares Outstanding61,622,799 shares (as of 2018-03-31)
Institutional Value$ 1,735,000 USD
Related CTYX / Connectyx Technologies Holdings Group, Inc.
CYTXW / Cytori Therapeutics, Inc. Warrants

Institutional Stock Ownership and Shareholders()

CYTX / Cytori Therapeutics, Inc. Institutional Ownership

Cytori Therapeutics, Inc. (NASDAQ:CYTX) has 37 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,762,305 shares. Largest shareholders include Perkins Capital Management Inc, Jefferies Group LLC, Vanguard Group Inc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Geode Capital Management, Llc, Virtu Financial LLC, Creative Planning, Susquehanna International Group, Llp, and Northern Trust Corp.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/cytx"><img src="https://images.fintel.io/us-cytx-so.png" alt="CYTX / Cytori Therapeutics, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Investment Management, LLC 3,531 3,531 0.00 7 5 -28.57
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 0 46,000 0 13
2018-05-14 13F-HR MORGAN STANLEY 2,258 2,258 0.00 1 1 0.00
2018-05-09 13F-HR BlackRock Inc. 319,328 316,734 -0.81 97 91 -6.19
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 718 718 0.00 0 0
2018-05-11 13F-HR MACQUARIE GROUP LTD 32,300 0 -100.00 10 0 -100.00
2018-04-23 13F-HR PERKINS CAPITAL MANAGEMENT INC 2,136,041 2,071,106 -3.04 644 593 -7.92
2018-05-15 13F-HR VANGUARD GROUP INC 552,666 606,749 9.79 166 174 4.82
2018-05-15 13F-HR JANE STREET GROUP, LLC 171,327 0 -100.00 52 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 166,315 166,315 0.00 49 47 -4.08
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 3,207 3,231 0.75 1 1 0.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,716 3,061 78.38 1 1 0.00
2018-04-18 13F-HR/A FNY Partners Fund LP 14,800 14,800 0.00 4 4 0.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 0 61 0 0
2018-05-14 13F-HR Virtu Financial LLC 0 143,401 0 41
2018-05-15 13F-HR BARCLAYS PLC 1,467 1,471 0.27 0 0
2017-01-13 13F-HR MetLife Securities, Inc 51 51 0.00 0 0
2018-05-09 13F-HR Lee Financial CORP 282 0
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 241 241 0.00 0 0
2018-05-01 13F-HR Plante Moran Financial Advisors, LLC 5,000 5,000 0.00 1 1 0.00
2018-05-03 13F-HR HUDSON CANYON INVESTMENT COUNSELORS LLC 6,342 2
2018-05-15 13F-HR BLAIR WILLIAM & CO/IL 25,087 7
2018-05-15 13F-HR HighTower Advisors, LLC 15,800 15,934 0.85 5 5 0.00
2018-05-15 13F-HR Bank of New York Mellon Corp 0 47,940 0 14
2018-05-09 13F-HR NORTHERN TRUST CORP 55,507 55,507 0.00 17 16 -5.88
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 21,540 0 -100.00 6 0 -100.00
2018-05-07 13F-HR Marathon Capital Management 11,335 11,335 0.00 3 3 0.00
2018-05-15 13F-HR Advisor Group, Inc. 160 160 0.00 0 0
2017-02-10 13F-HR BlackRock Fund Advisors 33,449 44,201 32.14 68 67 -1.47
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 253,335 253,335 0.00 514 383 -25.49
2018-05-15 13F-HR DEUTSCHE BANK AG\ 92 92 0.00 0 0
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 80,724 62,863 -22.13 24 18 -25.00
2018-05-15 13F-HR UBS Group AG 8,525 29,700 248.39 2 8 300.00
2018-05-15 13F-HR Jefferies Group LLC 0 746,367 0 214
2018-05-01 13F-HR Alpha Omega Wealth Management LLC 534 0
2018-05-15 13F-HR Intellectus Partners, LLC 20,000 30,000 50.00 6 9 50.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 13,226 13,226 0.00 4 4 0.00
2017-02-10 13F-HR BlackRock Advisors LLC 2,594 2,594 0.00 5 4 -20.00
2018-05-07 13F-HR Manchester Capital Management LLC 28 28 0.00 0 0
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 34 34 0.00 0 0
2018-04-18 13F-HR Creative Planning 78,077 78,077 0.00 23 22 -4.35
CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

10h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

11h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-3)

Cytori Therapeutics Erectile Dysfunction Stem Cell Therapy Shows Positive Results in Early Trial

2018-07-09 biospace
Cytori Therapeutics, headquartered in San Diego, published data from its clinical trial of Adipose-Derived Regenerative Cells (ADRCs) in the journal Urology showing positive results.

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics First Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions] (25-1)

BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial

2018-03-16 reuters
* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO’S PLANS FOR HABEO CELL THERAPY - SEC FILING (25-0)

CUSIP: 23283K105